White Pine Capital LLC Makes New $2.46 Million Investment in RadNet, Inc. $RDNT

White Pine Capital LLC bought a new stake in shares of RadNet, Inc. (NASDAQ:RDNT – Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 35,709 shares of the medical research company’s stock, valued at approximately $2,462,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Hantz Financial Services Inc. raised its holdings in shares of RadNet by 18.8% during the third quarter. Hantz Financial Services Inc. now owns 872 shares of the medical research company’s stock worth $60,000 after purchasing an additional 138 shares during the period. SteelPeak Wealth LLC boosted its holdings in shares of RadNet by 0.6% in the 3rd quarter. SteelPeak Wealth LLC now owns 25,251 shares of the medical research company’s stock valued at $1,741,000 after buying an additional 151 shares during the period. Arizona State Retirement System boosted its holdings in shares of RadNet by 0.9% in the 2nd quarter. Arizona State Retirement System now owns 18,203 shares of the medical research company’s stock valued at $1,123,000 after buying an additional 160 shares during the period. Oppenheimer & Co. Inc. boosted its holdings in shares of RadNet by 1.7% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 10,303 shares of the medical research company’s stock valued at $710,000 after buying an additional 175 shares during the period. Finally, PNC Financial Services Group Inc. grew its position in shares of RadNet by 2.9% during the 1st quarter. PNC Financial Services Group Inc. now owns 7,392 shares of the medical research company’s stock valued at $413,000 after buying an additional 207 shares during the last quarter. 77.90% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Mital Patel sold 44,661 shares of RadNet stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $78.51, for a total value of $3,506,335.11. Following the sale, the executive vice president directly owned 155,514 shares in the company, valued at $12,209,404.14. This trade represents a 22.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.14% of the stock is currently owned by corporate insiders.

RadNet Price Performance

Shares of NASDAQ RDNT opened at $76.42 on Monday. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.49 and a quick ratio of 1.49. The firm has a market capitalization of $6.02 billion, a PE ratio of -263.52 and a beta of 1.42. RadNet, Inc. has a 1-year low of $50.82 and a 1-year high of $85.84. The business’s fifty day moving average price is $72.78 and its two-hundred day moving average price is $65.51.

RadNet (NASDAQ:RDNT – Get Free Report) last announced its quarterly earnings results on Sunday, November 8th. The medical research company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.08. The company had revenue of $638.26 million during the quarter, compared to the consensus estimate of $639.97 million. RadNet had a negative net margin of 0.94% and a positive return on equity of 3.14%. The company’s revenue for the quarter was up 22.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.20 earnings per share. On average, research analysts expect that RadNet, Inc. will post 0.56 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. KeyCorp increased their price objective on shares of RadNet from $92.00 to $95.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 10th. Barclays raised their target price on shares of RadNet from $65.00 to $79.00 and gave the stock an “overweight” rating in a report on Friday, August 28th. Raymond James Financial restated a “strong-buy” rating on shares of RadNet in a research note on Tuesday, September 22nd. Zacks Research lowered RadNet from a “strong-buy” rating to a “hold” rating in a report on Monday, November 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of RadNet in a report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, RadNet presently has an average rating of “Moderate Buy” and an average price target of $89.67.

View Our Latest Analysis on RadNet

About RadNet

(Free Report)

RadNet, Inc. operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging. The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.

Featured Articles

Want to see what other hedge funds are holding RDNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RadNet, Inc. (NASDAQ:RDNT – Free Report).

Institutional Ownership by Quarter for RadNet (NASDAQ:RDNT)

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.